| UHC Commercial Medical & Drug | Lumvoa™ (Veligrotug-Vvze) and Tepezza® (Teprotumumab-Trbw) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Luxturna® (Voretigene Neparvovec-Rzyl) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Otarmeni™ (Lunsotogene Parvec-Cwha) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Respiratory Interleukin-5 Inhibitor – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Sodium Hyaluronate – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Zolgensma® (Onasemnogene Abeparvovec-Xioi) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Lumvoa™ (Veligrotug-Vvze) and Tepezza® (Teprotumumab-Trbw) – Community Plan Medical Benefit Drug Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Otarmeni™ (Lunsotogene Parvec-Cwha) – Community Plan Medical Benefit Drug Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Respiratory Interleukins – Community Plan Medical Benefit Drug Policy | 2026-10-01 |
| BCBS Highmark Delaware | Allergen Testing | 2026-10-01 |